Cover
Cover | May 16, 2024 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | At the time of the Original Filing, the Board had not made a determination regarding any committee assignments for Dr. Hohneker. This amended Current Report on Form 8-K is being filed to provide the committee assignment information omitted from the Original Filing. On July 3, 2024, the Board appointed Dr. Hohneker to the Nominating and Corporate Governance Committee and Compensation Committee of the Board, effective immediately. |
Document Period End Date | May 16, 2024 |
Entity File Number | 001-41929 |
Entity Registrant Name | ARRIVENT BIOPHARMA, INC. |
Entity Central Index Key | 0001868279 |
Entity Tax Identification Number | 86-3336099 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 18 Campus Boulevard |
Entity Address, Address Line Two | Suite 100 |
Entity Address, City or Town | Newtown Square |
Entity Address, State or Province | PA |
Entity Address, Postal Zip Code | 19073 |
City Area Code | 628 |
Local Phone Number | 277-4836 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value per share |
Trading Symbol | AVBP |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |